ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HEMO Hemogenyx Pharmaceuticals Plc

1.50
-0.015 (-0.99%)
Last Updated: 10:29:49
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.015 -0.99% 1.50 1.45 1.55 1.50 1.50 1.50 878,343 10:29:49
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.98M -0.0035 -4.31 17.24M
Hemogenyx Pharmaceuticals Plc is listed in the Finance Services sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 1.52p. Over the last year, Hemogenyx Pharmaceuticals shares have traded in a share price range of 1.125p to 6.30p.

Hemogenyx Pharmaceuticals currently has 1,141,999,321 shares in issue. The market capitalisation of Hemogenyx Pharmaceuticals is £17.24 million. Hemogenyx Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.31.

Hemogenyx Pharmaceuticals Share Discussion Threads

Showing 2001 to 2021 of 13425 messages
Chat Pages: Latest  81  80  79  78  77  76  75  74  73  72  71  70  Older
DateSubjectAuthorDiscuss
14/3/2020
16:03
Re Post 1329

I Googled :

"Neutralizing antibodies against emerging pathogens are going mainstream, Hemogenyx"

And the following article appeared on the first page, noting that the search indicated that the words "Neutralizing" and "Mainstream" were excluded.





Proactive

Hemogenyx develops new mouse model which could play a big role in future wars

08:26 Mon 24 Jun 2019

Hemogenyx thinks its new ApbHC mouse model could be used to rapidly develop antibodies to treat deadly pathogens such as Anthrax released as an act of war

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has developed a new generation of humanised mice which it believes could play a vital role in protecting people caught up in biological warfare.

Governments spend billions of dollars every year protecting their citizens from the threat of biological weapons, such as the release of pathogens and toxins including anthrax and smallpox.

Hemogenyx thinks its new mouse model, called Advanced peripheral blood Hematopoietic Chimera (ApbHC), could potentially be used to help rapidly develop treatments against unknown human-specific pathogens.

ApbHC has “several advantages” over other mouse models, says Hemogenyx, including the absence of Graft versus Host disease – when the mouse rejects the transplanted tissue – which makes the use of certain cells impossible.

Article continues.......

tullynessle
14/3/2020
15:31
Purple Post 1327

1328 prepared concurrently with your 1327.

I agree with your thoughts that Lilly may be the global co partner?

I suppose there has to be some reasons for Hemogenyx to highlight the News Release, although it many be as simple as general interest in medical/research process, progress in managing the pandemic, or reference to "Neutralizing antibodies against emerging pathogens are going mainstream."

tullynessle
14/3/2020
15:25
Hemogenyx highlighted the Lilly News Release in its tweet, however not sure which component of the research / discovery process is similar to Hemogenyx technology, (if any).

I noticed that the document mentions that "our goal with AbCellera is to be testing potential new therapies in patients within the next four months." so that appears to be good news.





03/12/2020

AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-

VANCOUVER, British Columbia and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.

Within one week of receiving a blood sample from one of the first U.S. patients who recovered from COVID-19, AbCellera screened over 5 million immune cells looking for ones that produced functional antibodies that helped the patient neutralize the virus and recover from the disease. From this effort, AbCellera has identified over 500 unique fully human antibody sequences, the largest panel of anti-SARS-CoV-2 antibodies ever reported. The next step is to screen these antibodies to find the ones most effective in neutralizing SARS-CoV-2. Many of these antibodies will be expressed in collaboration with partners at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and pending agreement with NIAID will be tested for their ability to neutralize the virus.

"AbCellera's platform has delivered, with unprecedented speed, by far the world's largest panel of anti-SAR-CoV-2 antibodies," said Carl Hansen, Ph.D., CEO of AbCellera. "In 11 days, we've discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the world's leading biopharmaceutical companies. We're deeply impressed with the speed and agility of Lilly's response to this global challenge. Together, our teams are committed to delivering a countermeasure to stop the outbreak."

"With the number of cases rapidly increasing all over the world, doctors and patients are seeking a therapeutic intervention that can speed their recovery or prevent the disease. Lilly is committed to playing our part to bring innovation to patients amidst this global outbreak," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "We've partnered with AbCellera because we're impressed with the speed and quality of their efforts. We are moving at top speed to create a potential treatment to help patients. While typically a new therapeutic antibody program might take years to get in the clinic, our goal with AbCellera is to be testing potential new therapies in patients within the next four months."

Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution. If successful, Lilly is ready to work with global regulators to bring a treatment to patients.

==============================


Hemogenyx
@HemoGenyx
·
4h
Neutralizing antibodies against emerging pathogens are going mainstream.

tullynessle
14/3/2020
15:09
hemogenyx tweeting about lilly.is this the global co partner?






Hemogenyx

@HemoGenyx


Neutralizing antibodies against emerging pathogens are going mainstream.



AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 | Eli Lilly and...
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

investor.lilly.com

purple11
14/3/2020
11:56
Seems to have nothing to do with Hemogenyx...!!

I have written to the Dr , but so far he has failed to respond to my many questions

johntopdog
13/3/2020
13:46
Agree i don't think it's a good time for Hemo to be agreeing a deal and probably not for a pharma company either. Big pharma who source most raw materials from China must be hurting.

Hemo have a years cash, they should get on with background works and given Dr Vlad and Sir Feldmanns ages I hope they put their own health first in these worrying times. Work from home, can't cure anyone if they fall badly ill.

Look after yourselves board members, long and short. We're mostly human.

PS I've saved myself £270k in the past 2 months, stick that up your imaginary trading apps pipe. So long

quickdraw18
12/3/2020
16:23
I doubt we'll be getting an rns until the market settles down.it would just be lost in this carnage.
purple11
12/3/2020
16:18
im not putting anymore in here.i have what I have.
But for new investors could be a fantastic entry.

purple11
12/3/2020
16:14
It's a great time to have a load of spare cash to invest. Pity I don't have any.
on target
12/3/2020
16:11
when will this end/its just another seasonal flu.absolutely bonkers.
purple11
12/3/2020
16:06
ftse down 10.8%!!
purple11
12/3/2020
15:48
Can buy 2m online at the moment if dummy quotes are to be believed. Not sure what would happen if I had the cash and pressed the button though.
on target
12/3/2020
15:31
should start attracting some buying now once the market settles...…..
purple11
12/3/2020
15:29
5.8m cap now
purple11
12/3/2020
14:00
Marie, stop writing stuff like you knew what this company is about. The only reason you say it's a scam is because what I've told you. You were yet another clueless investor, you even copied word for word my questions to the company.

You didn't find out it's a scam, I did. You're still licking your wounds at a loss, or you gonna tell us you're shorting it now 😂

davevt
12/3/2020
11:05
Okay members,

Time to say goodbye. Left so many footprints here but brace for another ID soon.

I want to enjoy my winning for few days.

Bye bye to Dartford boys. I used to Andy them but they both dumped me:

Right, you won’t hear from me from this id:

Bye bye

make_some_noise_4_dartford_boys
12/3/2020
11:00
stick to Bingo.
better odds

purple11
12/3/2020
09:57
Purple see SNG
NOW ONWARD I WILL CHARGE YOU FOR MY TIP

I’m not idiot like DAVE

make_some_noise_4_dartford_boys
12/3/2020
09:52
Cull purple cull
Everyone idiot should deserve to lose 90% here and in broader market

2008 didn’t give any lesson to anyone

Spartaaaaaa

make_some_noise_4_dartford_boys
12/3/2020
09:40
Patience needed.

Kept hearing this.

It’s not a rocket science to understand that this is scam.

Don’t believe me:

Scan all their RNS again.

2 years is not a small time:

Remember no IND news

And wtf is that “globalco̶1;

You just couldn’t make it up lol

make_some_noise_4_dartford_boys
12/3/2020
09:28
Purple;

I’m waiting for your legendary sentence


What a useless thread this is

Same like HEMO: what a scam company this is haha

I’m surprised Dr. Didn’t put RNS of corona virus

I would have died in that case lol

You just couldn’t make it up hahaha


SPARTAAAAAAA

make_some_noise_4_dartford_boys
Chat Pages: Latest  81  80  79  78  77  76  75  74  73  72  71  70  Older

Your Recent History